Translational Research, published by Elsevier Science Inc, stands at the forefront of the rapidly evolving fields of biochemistry, medicine, physiology, and public health. With an impressive 2023 Q1 ranking in these categories, this journal has established itself as a critical platform for disseminating innovative research that bridges the gap between laboratory findings and clinical application. The journal, which has been converging knowledge since 2006, is committed to advancing scientific understanding and improving health outcomes by publishing high-quality articles that reflect rigorous peer review and impactful findings. With its impressive Scopus rankings, including a rank of #5 in Biochemistry and #7 in Physiology, it is an essential resource for researchers, practitioners, and students dedicated to the translation of scientific breakthroughs into real-world health solutions. Transitioning to an open-access model, the journal enhances accessibility and engagement, inviting a global audience to participate in the discourse shaping the future of healthcare and disease management.

Expert Opinion on Therapeutic Targets, published by Taylor & Francis Ltd, is a highly respected journal in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. With a focus on cutting-edge research and innovative approaches to therapeutic development, this journal has established itself as a leading platform for scholars and practitioners, boasting a prestigious Q1 ranking across multiple categories in 2023. The journal aims to present expert perspectives on novel therapeutic strategies, promising drug candidates, and insights into the intricate mechanisms underlying various diseases. Its impressive impact factor reflects the journal's commitment to advancing scientific knowledge and influencing clinical practice. With its inception in 1997 and ongoing publication through to 2024, Expert Opinion on Therapeutic Targets continues to be an invaluable resource for those seeking to stay at the forefront of therapeutic innovations.

Cancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.

Laboratory Investigation is a premier academic journal published by Elsevier Science Inc, specializing in the fields of Pathology, Forensic Medicine, Cell Biology, and Molecular Biology. With its ISSN 0023-6837 and E-ISSN 1530-0307, this journal has been a significant contributor to scientific discourse since its inception in 1952, converging into its current form by 2024. It holds an impressive standing in its respective fields, featuring a 2023 Journal Rank of Q2 in both Cell Biology and Molecular Biology, and an elite Q1 ranking in Pathology and Forensic Medicine, reflecting its influence and quality of research, as seen in its Scopus ranks—17th out of 208 in Pathology and Forensic Medicine. Although it does not offer Open Access options, the journal remains a vital resource for researchers, professionals, and students who seek to disseminate and engage with high-caliber research findings. The importance of Laboratory Investigation is underscored by its commitment to advancing the understanding of laboratory and translational medicine, paving the way for innovations that enhance clinical practices.

Current Opinion in Pharmacology, an esteemed journal published by Elsevier Science Ltd, encompasses the vital field of pharmacology and drug discovery. With a solid impact factor and recognized as a Q1 journal in both Drug Discovery and Pharmacology categories for 2023, it serves as a premier platform for researchers and professionals to share innovative insights, discuss emerging trends, and explore the complexities of drug development and therapeutic applications. Established in 2001 and running through 2024, this journal provides a critical overview of advances in the field, aiming to inform and inspire the next generation of pharmacological research. Despite lacking Open Access options, it maintains a high standard of scholarly excellence, ensuring that the content remains impactful and relevant to its readers. The journal is based in the Netherlands, representing a key contributor to the academic landscape in pharmacology.

Cancer Discovery, published by the American Association for Cancer Research, stands as a vital resource in the oncological research community, renowned for its commitment to disseminating groundbreaking studies and innovative findings in cancer biology, prevention, diagnostics, and treatment. With a significant impact factor reflecting its esteemed position, this journal facilitates open discussions and collaborations, striving to bridge the gap between experimental and clinical research. The journal, which has been active since 2011, is classified as a Q1 publication in 2023, underscoring its influence and authority in the realm of Oncology. By providing a platform for rigorous peer-reviewed articles, Cancer Discovery aims to advance our understanding of cancer and enhance therapeutic strategies, making it an indispensable tool for researchers, professionals, and students eager to stay at the forefront of cancer research.

EBioMedicine is an esteemed open-access journal published by ELSEVIER, dedicated to advancing the fields of biochemistry, genetics, and molecular biology, as well as medicine. Since its inception in 2014, EBioMedicine has established itself as a prominent platform for disseminating high-quality research, evidenced by its impressive rankings in Scopus, where it holds a Q1 category in both Biochemistry, Genetics and Molecular Biology and Medicine for 2023. With an exceptional impact factor that places it in the top percentiles (97th in Medicine and 93rd in Biochemistry), the journal is recognized for its rigorous peer-review process and its commitment to fostering scientific collaboration. Open access since its launch, EBioMedicine ensures that groundbreaking research is readily available to researchers, professionals, and students worldwide, enhancing knowledge dissemination and driving innovation in these crucial fields. For those seeking to stay at the forefront of biomedical research, EBioMedicine is an invaluable resource.

International Cardiovascular Research Journal, published by Shiraz University Medical Sciences, serves as a vital platform for the dissemination of cutting-edge research in the field of cardiology and cardiovascular medicine. Since its inception in 2011, this journal has continuously devoted itself to promoting the highest quality of scholarly communication, helping to bridge the gap between laboratory findings and clinical application. With an ISSN of 2251-9130 and an E-ISSN of 2251-9149, it is indexed in prominent databases, contributing to its visibility and accessibility to a global audience. Although currently classified in the Q4 quartile in the 2023 rankings, the journal is committed to enhancing its impact factor and academic stature. It aims to facilitate open access for all published articles, although specific details on access options are pending. Through its rigorous peer-review process and diverse scope—which encapsulates advancements, clinical studies, and innovative therapeutic strategies—this journal fosters academic collaboration in the realm of cardiovascular health, making it an invaluable resource for researchers, practitioners, and students alike.

IN VIVO is a prestigious academic journal published by the International Institute of Anticancer Research, dedicated to advancing the fields of biochemistry, genetics, molecular biology, cancer research, and pharmacology. With its ISSN 0258-851X and E-ISSN 1791-7549, this journal has been a key contributor to innovative research since its inception in 1987, providing a crucial platform for the dissemination of significant findings in its scope. With an impressive impact reflected in its quartile rankings (Q2 in Biochemistry, Genetics and Molecular Biology and Medicine; Q3 in Cancer Research and Pharmacology), IN VIVO reaches a global audience comprising researchers, health professionals, and students. Although it operates on a subscription basis, the journal’s commitment to scientific excellence and rigorous peer review ensures that all published works maintain high quality and relevance. Notably positioned in Scopus ranks within the 36th to 59th percentiles across various categories, IN VIVO continues to be a vital resource for cutting-edge research and developments, solidifying its importance within the scientific community.

Biomedicines, published by MDPI, is a prestigious open-access journal dedicated to the rapidly evolving fields of biochemistry, genetics, and molecular biology, as well as broader aspects of medicine. Since its inception in 2013, Biomedicines has established itself as a leading platform for researchers, practitioners, and students to disseminate high-quality research and innovative findings, reflected in its impressive Q1 ranking in both the Biochemistry, Genetics and Molecular Biology and Medicine categories. With its commitment to accessibility and impactful scholarship, the journal has quickly garnered an international readership, positioning itself as a vital resource in advancing scientific knowledge and fostering collaboration in the biomedical community. Operating from its headquarters in Basel, Switzerland, Biomedicines continues to thrive with features such as rigorous peer review and a fast publication process, making it an essential journal for those looking to contribute to and stay updated in their respective fields.